Skip to content
Our 2022 Year in Review is now live.
  • Insights

      Weekly Bulletin

      Your weekly recap of news and analysis from the psychedelic sector.

      Read the Latest

      Research Review

      A monthly review of the most important psychedelics research.

      Review Archive

      News & Interviews

      The latest news from across the psychedelics space.

      Explore Now
  • Data

      Psychedelics Patent Trackers

      We track the latest patents and filings related to psilocybin, MDMA and DMT.

      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents
      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents

      Psychedelic Legalization & Decriminalization Tracker

      Mapping psychedelic drug policy reform across the United States

      Explore the Tracker
      New: Oregon Local Jurisdiction Tracker

      Psychedelics Drug Development Tracker

      From drug discovery to regulatory approval, we map drug development in psychedelics.

      Explore the Tracker
  • Companies

      Stocks & Companies Directory

      A directory of all the major psychedelics stocks, companies and ETFs.

      Access Directory

      Sector Landscape Map

      Explore the Psychedelic Sector Landscape visually using our new tool.

      Explore Now

      Stock Watchlist

      A one-stop overview of psychedelics stocks financial performance.

      Explore Now
  • Psychedelic Careers
  • Contact
Search
Close
Read more about the article Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS

Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS

  • Post published:January 5, 2023
  • Post category:Announcements
Read more about the article MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

  • Post published:November 17, 2022
  • Post category:News/Press Release
Read more about the article Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial

Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial

  • Post published:December 2, 2020
  • Post category:Press Release
Read more about the article MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

  • Post published:October 27, 2020
  • Post category:Press Release
Read more about the article Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval

Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval

  • Post published:August 20, 2020
  • Post category:Press Release
Read more about the article MAPS announces $30m, 90-day Capstone Challenge to Finalise MDMA as Medicine for PTSD; Tim Ferriss Donates $1m

MAPS announces $30m, 90-day Capstone Challenge to Finalise MDMA as Medicine for PTSD; Tim Ferriss Donates $1m

  • Post published:June 21, 2020
  • Post category:News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Psychedelic Stocks and Companies
  • News & Interviews
  • Psychedelic Sector Jobs
  • Data Bank

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

  • Psychedelic Alpha © 2022, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.